Cargando…
Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction
Background and Objectives: Approximately 10–15% of high-grade serous ovarian cancer (HGSOC) cases are related to BRCA germline mutations. Better survival rates and increased chemosensitivity are reported in patients with a BRCA 1/2 germline mutation. However, the FIGO stage and histopathological ent...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699274/ https://www.ncbi.nlm.nih.gov/pubmed/36363568 http://dx.doi.org/10.3390/medicina58111611 |
_version_ | 1784839032062083072 |
---|---|
author | De Jong, Diederick Otify, Mohamed Chen, Inga Jackson, David Jayasinghe, Kelum Nugent, David Thangavelu, Amudha Theophilou, Georgios Laios, Alexandros |
author_facet | De Jong, Diederick Otify, Mohamed Chen, Inga Jackson, David Jayasinghe, Kelum Nugent, David Thangavelu, Amudha Theophilou, Georgios Laios, Alexandros |
author_sort | De Jong, Diederick |
collection | PubMed |
description | Background and Objectives: Approximately 10–15% of high-grade serous ovarian cancer (HGSOC) cases are related to BRCA germline mutations. Better survival rates and increased chemosensitivity are reported in patients with a BRCA 1/2 germline mutation. However, the FIGO stage and histopathological entity may have been confounding factors. This study aimed to compare chemotherapy response and survival between patients with and without a BRCA 1/2 germline mutation in advanced HGSOC receiving neoadjuvant chemotherapy (NACT). Materials and Methods: A cohort of BRCA-tested advanced HGSOC patients undergoing cytoreductive surgery following NACT was analyzed for chemotherapy response and survival. Neoadjuvant chemotherapy served as a vehicle to assess chemotherapy response on biochemical (CA125), histopathological (CRS), biological (dissemination), and surgical (residual disease) levels. Univariate and multivariate analyses for chemotherapy response and survival were utilized. Results: Thirty-nine out of 168 patients had a BRCA ½ germline mutation. No differences in histopathological chemotherapy response between the patients with and without a BRCA ½ germline mutation were observed. Survival in the groups of patients was comparable Irrespective of the BRCA status, CRS 2 and 3 (HR 7.496, 95% CI 2.523–22.27, p < 0.001 & HR 4.069, 95% CI 1.388–11.93, p = 0.011), and complete surgical cytoreduction (p = 0.017) were independent parameters for a favored overall survival. Conclusions: HGSOC patients with or without BRCA ½ germline mutations, who had cytoreductive surgery, showed comparable chemotherapy responses and subsequent survival. Irrespective of BRCA status, advanced-stage HGSOC patients have a superior prognosis with complete surgical cytoreduction and good histopathological response to chemotherapy. |
format | Online Article Text |
id | pubmed-9699274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96992742022-11-26 Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction De Jong, Diederick Otify, Mohamed Chen, Inga Jackson, David Jayasinghe, Kelum Nugent, David Thangavelu, Amudha Theophilou, Georgios Laios, Alexandros Medicina (Kaunas) Article Background and Objectives: Approximately 10–15% of high-grade serous ovarian cancer (HGSOC) cases are related to BRCA germline mutations. Better survival rates and increased chemosensitivity are reported in patients with a BRCA 1/2 germline mutation. However, the FIGO stage and histopathological entity may have been confounding factors. This study aimed to compare chemotherapy response and survival between patients with and without a BRCA 1/2 germline mutation in advanced HGSOC receiving neoadjuvant chemotherapy (NACT). Materials and Methods: A cohort of BRCA-tested advanced HGSOC patients undergoing cytoreductive surgery following NACT was analyzed for chemotherapy response and survival. Neoadjuvant chemotherapy served as a vehicle to assess chemotherapy response on biochemical (CA125), histopathological (CRS), biological (dissemination), and surgical (residual disease) levels. Univariate and multivariate analyses for chemotherapy response and survival were utilized. Results: Thirty-nine out of 168 patients had a BRCA ½ germline mutation. No differences in histopathological chemotherapy response between the patients with and without a BRCA ½ germline mutation were observed. Survival in the groups of patients was comparable Irrespective of the BRCA status, CRS 2 and 3 (HR 7.496, 95% CI 2.523–22.27, p < 0.001 & HR 4.069, 95% CI 1.388–11.93, p = 0.011), and complete surgical cytoreduction (p = 0.017) were independent parameters for a favored overall survival. Conclusions: HGSOC patients with or without BRCA ½ germline mutations, who had cytoreductive surgery, showed comparable chemotherapy responses and subsequent survival. Irrespective of BRCA status, advanced-stage HGSOC patients have a superior prognosis with complete surgical cytoreduction and good histopathological response to chemotherapy. MDPI 2022-11-08 /pmc/articles/PMC9699274/ /pubmed/36363568 http://dx.doi.org/10.3390/medicina58111611 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Jong, Diederick Otify, Mohamed Chen, Inga Jackson, David Jayasinghe, Kelum Nugent, David Thangavelu, Amudha Theophilou, Georgios Laios, Alexandros Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title | Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title_full | Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title_fullStr | Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title_full_unstemmed | Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title_short | Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction |
title_sort | survival and chemosensitivity in advanced high grade serous epithelial ovarian cancer patients with and without a brca germline mutation: more evidence for shifting the paradigm towards complete surgical cytoreduction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699274/ https://www.ncbi.nlm.nih.gov/pubmed/36363568 http://dx.doi.org/10.3390/medicina58111611 |
work_keys_str_mv | AT dejongdiederick survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT otifymohamed survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT cheninga survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT jacksondavid survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT jayasinghekelum survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT nugentdavid survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT thangaveluamudha survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT theophilougeorgios survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction AT laiosalexandros survivalandchemosensitivityinadvancedhighgradeserousepithelialovariancancerpatientswithandwithoutabrcagermlinemutationmoreevidenceforshiftingtheparadigmtowardscompletesurgicalcytoreduction |